Icosavax, Inc.
ICVXDelisted- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001786255
Icosavax, Inc. was delisted in 2024; its insiders filed their last Form 4 on Feb 20, 2024; 93 institutions reported holding it in 13F filings for Q4 2023, worth $664.5M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Icosavax, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Icosavax, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| RA Capital Healthcare Fund LP | Director, 10% Owner | 0Indirect | Feb 20, 2024 | 0 |
| Ra Capital Management, L.P. | Director, 10% Owner | 0Indirect | Feb 20, 2024 | 0 |
| Kolchinsky Peter | Director, 10% Owner | 0Indirect | Feb 20, 2024 | 0 |
| Shah Rajeev M. | Director, 10% Owner | 0Indirect | Feb 20, 2024 | 0 |
| RA Capital Nexus Fund II, L.P. | Director, 10% Owner | 0Indirect | Feb 20, 2024 | 0 |
| Fields Heidi | Other: See Remarks | 0 | Feb 20, 2024 | 0 |
| McDade Mark | Other: See Remarks | 0Indirect | Feb 20, 2024 | 0 |
| Veneman Ann M | Other: See Remarks | 0 | Feb 20, 2024 | 0 |
| Russo Thomas Joseph | Other: See Remarks | 0 | Feb 20, 2024 | 0 |
| Wassil Jim | Other: See Remarks | 0 | Feb 20, 2024 | 0 |
| Simpson Adam K. | Other: See Remarks | 0Indirect | Feb 20, 2024 | 0 |
| Cearley Cassia | Other: See Remarks | 0 | Feb 20, 2024 | 0 |
| Kanesa-thasan Niranjan | Other: See Remarks | 0 | Feb 20, 2024 | 0 |
| Shiver John W. | Other: See Remarks | 0 | Feb 20, 2024 | 0 |
| Khan Amin | Other: See Remarks | – | Feb 20, 2024 | 0 |
| Holtzman Douglas | Chief Scientific Officer | 290,054 | Jul 3, 2023 | 0 |
| RA Capital Nexus Fund, L.P. | Director, 10% Owner | – | Jun 8, 2023 | 0 |
| Bekiroglu Elizabeth | General Counsel & Corp. Sec. | 103,007 | Feb 17, 2023 | 0 |
| Richardson Charles E | SVP, Technical Operations | 165,168 | Aug 2, 2022 | 0 |
| Nicholson Jonathan | Other: Former 10% Owner | 2,883,329 | Aug 4, 2021 | 0 |
| NanoDimension III, L.P. | Other: Former 10% Owner | 2,883,329 | Aug 4, 2021 | 0 |
| NanoDimension III Management Ltd | Other: Former 10% Owner | 2,883,329 | Aug 4, 2021 | 0 |
| NanoDimension III GP Limited Partnership | Other: Former 10% Owner | 2,883,329 | Aug 4, 2021 | 0 |
| Cormorant Asset Management, LP | Other: Former 10% Owner | 426,393Indirect | Aug 4, 2021 | 0 |
| Chen Bihua | Other: Former 10% Owner | 426,393Indirect | Aug 4, 2021 | 0 |
| Cormorant Global Healthcare Master Fund, LP | Other: Former 10% Owner | 426,393Indirect | Aug 4, 2021 | 0 |
| Cormorant Private Healthcare Fund III LP | Other: Former 10% Owner | 426,393Indirect | Aug 4, 2021 | 0 |
| Adams Street Partners LLC | Other: Former 10% Owner | 256,783Indirect | Aug 3, 2021 | 0 |
| Gould Terry P | Director | 256,783Indirect | Aug 3, 2021 | 0 |
| Qiming U.S. Healthcare Fund II, L.P. | Other: Former 10% Owner | 3,523,561 | Aug 2, 2021 | 0 |
| Qiming U.S. Healthcare GP II, LLC | Other: Former 10% Owner | 3,523,561 | Aug 2, 2021 | 0 |
| Sanofi | 10% Owner | 3,155,169Indirect | Aug 2, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 2, 2024 (view filing) | Feb 1 | 1 day | Simpson Adam K.Chief Executive Officer | SSale | −15.0K | $15.29 | −$229.3K | −4.0%358.7K after | 10b5-1 |
| Jan 5, 2024 (view filing) | Jan 4, 2023 | 366 daysLate | Kanesa-thasan NiranjanChief Medical Officer | SSale | −106.4K | $15.70 | −$1.67M | −32.2%224.0K after | |
| Jan 4, 2024 (view filing) | Jan 2 | 2 days | Simpson Adam K.Chief Executive Officer | SSale | −15.0K | $15.67 | −$235.1K | −5.4%260.6K after | 10b5-1 |
| Dec 22, 2023 (view filing) | Dec 20-21 | 2 days | Simpson Adam K.Chief Executive Officer | SSale | −152.2K | $15.45 | −$2.35M | −36.9%260.6K after | 3 lots10b5-1 |
| Dec 22, 2023 (view filing) | Dec 20 | 2 days | Russo Thomas JosephChief Financial Officer | SSale | −15.2K | $15.46 | −$234.8K | −28.5%38.0K after | 2 lots |
| Dec 22, 2023 (view filing) | Dec 20 | 2 days | Kanesa-thasan NiranjanChief Medical Officer | SSale | −11.9K | $15.46 | −$183.7K | −5.0%224.0K after | |
| Dec 22, 2023 (view filing) | Dec 20 | 2 days | Cearley CassiaChief Business Officer | SSale | −7.93K | $15.46 | −$122.7K | −5.7%130.7K after | |
| Dec 15, 2023 (view filing) | Dec 13 | 2 days | Cearley CassiaChief Business Officer | SSale | −8.76K | $16.01 | −$140.2K | −6.3%131.2K after | 10b5-1 |
| Aug 1, 2023 (view filing) | Jul 31 | 1 day | Kanesa-thasan NiranjanChief Medical Officer | SSale | −3.32K | $8.86 | −$29.4K | −1.4%235.9K after | 10b5-1 |
| Aug 1, 2023 (view filing) | Jul 31 | 1 day | Simpson Adam K.Chief Executive Officer | SSale | −11.8K | $8.86 | −$104.4K | −4.6%243.9K after | 10b5-1 |
| Aug 1, 2023 (view filing) | Jul 31 | 1 day | Russo Thomas JosephChief Financial Officer | SSale | −3.07K | $8.86 | −$27.2K | −6.3%45.6K after | 10b5-1 |
| Aug 1, 2023 (view filing) | Jul 31 | 1 day | Cearley CassiaChief Business Officer | SSale | −1.89K | $8.86 | −$16.7K | −1.3%140.0K after | 10b5-1 |
| Jul 3, 2023 (view filing) | Jul 3 | Same day | Holtzman DouglasChief Scientific Officer | SSale | −16.4K | $8.85 | −$144.7K | −5.3%290.1K after | 2 lots10b5-1 |
| May 25, 2023 (view filing) | May 23 | 2 days | Cearley CassiaChief Business Officer | SSale | −10.0K | $10.00 | −$100.0K | −6.6%141.8K after | 10b5-1 |
| Apr 5, 2023 (view filing) | Apr 3 | 2 days | Holtzman DouglasChief Scientific Officer | SSale | −20.4K | $6.09 | −$124.4K | −6.6%290.1K after | 2 lots10b5-1 |
| Mar 8, 2023 (view filing) | Mar 6 | 2 days | Cearley CassiaChief Business Officer | SSale | −5.00K | $7.75 | −$38.8K | −3.2%151.8K after | |
| Feb 15, 2023 (view filing) | Feb 13 | 2 days | Bekiroglu ElizabethGeneral Counsel & Corp. Sec. | SSale | −5.92K | $10.69 | −$63.3K | −5.4%103.0K after | |
| Feb 15, 2023 (view filing) | Feb 13 | 2 days | Simpson Adam K.Chief Executive Officer | SSale | −7.51K | $10.69 | −$80.2K | −3.0%245.0K after | |
| Feb 15, 2023 (view filing) | Feb 13-14 | 2 days | Holtzman DouglasChief Scientific Officer | SSale | −4.87K | $10.33 | −$50.3K | −1.7%290.1K after | 2 lots |
| Feb 15, 2023 (view filing) | Feb 13 | 2 days | Russo Thomas JosephChief Financial Officer | SSale | −1.90K | $10.69 | −$20.3K | −3.8%48.7K after | |
| Feb 15, 2023 (view filing) | Feb 13 | 2 days | Kanesa-thasan NiranjanChief Medical Officer | SSale | −1.79K | $10.69 | −$19.2K | −0.7%239.2K after | |
| Feb 15, 2023 (view filing) | Feb 13 | 2 days | Cearley CassiaChief Business Officer | SSale | −1.66K | $10.69 | −$17.7K | −1.0%156.8K after | |
| Dec 23, 2022 (view filing) | Dec 21 | 2 days | Simpson Adam K.Chief Executive Officer | SSale | −66.8K | $8.96 | −$598.2K | −22.9%225.1K after | |
| Dec 16, 2022 (view filing) | Dec 15 | 1 day | Holtzman DouglasChief Scientific Officer | SSale | −19.6K | $11.14 | −$218.9K | −87.6%2.79K after | |
| Sep 9, 2022 (view filing) | Sep 8 | 1 day | Bekiroglu ElizabethGeneral Counsel & Corp. Sec. | SSale | −1.81K | $4.87 | −$8.83K | −1.6%108.9K after | |
| Aug 2, 2022 (view filing) | Jul 29-Aug 2 | 4 days | Simpson Adam K.Chief Executive Officer | SSale | −11.4K | $6.75 | −$76.8K | −3.8%291.9K after | 3 lots |
| Aug 2, 2022 (view filing) | Jul 29-Aug 2 | 4 days | Russo Thomas JosephChief Financial Officer | SSale | −2.96K | $6.75 | −$20.0K | −5.7%48.9K after | 3 lots |
| Aug 2, 2022 (view filing) | Jul 29-Aug 2 | 4 days | Holtzman DouglasChief Scientific Officer | SSale | −10.4K | $6.67 | −$69.2K | −3.4%293.3K after | 3 lots |
| Aug 2, 2022 (view filing) | Jul 29-Aug 2 | 4 days | Richardson Charles ESVP, Technical Operations | SSale | −2.22K | $6.75 | −$15.0K | −1.3%165.2K after | 3 lots |
| Aug 2, 2022 (view filing) | Jul 29-Aug 2 | 4 days | Kanesa-thasan NiranjanChief Medical Officer | SSale | −3.25K | $6.75 | −$21.9K | −1.3%239.3K after | 3 lots |
| Aug 2, 2022 (view filing) | Jul 29-Aug 2 | 4 days | Cearley CassiaChief Business Officer | SSale | −1.81K | $6.75 | −$12.2K | −1.4%131.7K after | 3 lots |
| Apr 5, 2022 (view filing) | Apr 1 | 4 days | McDade MarkDirector | PPurchase | +42.2K | $7.10 | +$299.8K | +526.6%50.2K after | |
| Mar 30, 2022 (view filing)4:31 PM ET | Mar 28-29 | 2 days | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | PPurchase | +184.2K | $4.54 | +$836.9K | +3.2%5.96M after | 2 lots |
| Mar 9, 2022 (view filing) | Mar 7 | 2 days | Cearley CassiaChief Business Officer | SSale | −10.0K | $17.16 | −$171.6K | −9.2%98.4K after | 2 lots |
| Aug 4, 2021 (view filing)6:20 PM ET | Aug 2 | 2 days | Nicholson Jonathan and 3 othersOther: Former 10% Owner | PPurchase | +133.3K | $15.00 | +$2.00M | +4.8%2.88M after | |
| Aug 4, 2021 (view filing)4:31 PM ET | Aug 2 | 2 days | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | PPurchase | +2.67M | $15.00 | +$40.0M | New position638.7K after | 2 lots |
| Aug 3, 2021 (view filing) | Aug 2 | 1 day | Adams Street Partners LLCOther: Former 10% Owner | PPurchase | +133.3K | $15.00 | +$2.00M | +108.0%256.8K after | 4 lotsDuplicate filing |
| Aug 3, 2021 (view filing) | Aug 2 | 1 day | Gould Terry PDirector | PPurchase | +133.3K | $15.00 | +$2.00M | +108.0%256.8K after | 4 lots |
| Aug 2, 2021 (view filing)9:27 PM ET | Aug 2 | Same day | McDade Mark and 2 othersOther: Former 10% Owner | PPurchase | +221.4K | $15.00 | +$3.32M | +6.7%3.52M after | 3 lots |
| Aug 2, 2021 (view filing) | Aug 2 | Same day | Kanesa-thasan NiranjanChief Medical Officer | PPurchase | +6.67K | $15.00 | +$100.0K | New position6.67K after | |
| Aug 2, 2021 (view filing) | Aug 2 | Same day | Sanofi10% Owner | PPurchaseCommon Stock (par value, $0.0001) | +66.7K | $15.00 | +$1.00M | +2.2%3.16M after |